{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T00:41:36Z","timestamp":1724978496325},"reference-count":4,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,8,21]],"date-time":"2024-08-21T00:00:00Z","timestamp":1724198400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,21]],"date-time":"2024-08-21T00:00:00Z","timestamp":1724198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Innere Medizin"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s00108-024-01730-2","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T06:55:32Z","timestamp":1724396132000},"page":"962-964","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Neue Therapieoptionen bei prim\u00e4r bili\u00e4rer Cholangitis","New treatment options for primary biliary cholangitis"],"prefix":"10.1007","volume":"65","author":[{"given":"Verena","family":"Keitel-Anselmino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sirka","family":"Nitschmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,21]]},"reference":[{"key":"1730_CR1","doi-asserted-by":"publisher","unstructured":"European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. J\u00a0Hepatol. 2017 Jul;67(1):145\u2013172. https:\/\/doi.org\/10.1016\/j.jhep.2017.03.022. Epub 2017 Apr 18. PMID: 28427765.","DOI":"10.1016\/j.jhep.2017.03.022"},{"issue":"7","key":"1730_CR2","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1056\/NEJMoa1509840","volume":"375","author":"F Nevens","year":"2016","unstructured":"Nevens\u00a0F, Andreone\u00a0P, Mazzella\u00a0G, Strasser\u00a0SI, Bowlus\u00a0C, Invernizzi\u00a0P, Drenth\u00a0JP, Pockros\u00a0PJ, Regula\u00a0J, Beuers\u00a0U, Trauner\u00a0M, Jones\u00a0DE, Floreani\u00a0A, Hohenester\u00a0S, Luketic\u00a0V, Shiffman\u00a0M, van Erpecum\u00a0KJ, Vargas\u00a0V, Vincent\u00a0C, Hirschfield\u00a0GM, Shah\u00a0H, Hansen\u00a0B, Lindor\u00a0KD, Marschall\u00a0HU, Kowdley\u00a0KV, Hooshmand-Rad\u00a0R, Marmon\u00a0T, Sheeron\u00a0S, Pencek\u00a0R, MacConell\u00a0L, Pruzanski\u00a0M, Shapiro\u00a0D, POISE Study Group. A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis. N Engl J Med. (2016) Aug 18. PMID: 375(7):631\u2013643. https:\/\/doi.org\/10.1056\/NEJMoa1509840 (27532829)","journal-title":"PMID:"},{"issue":"23","key":"1730_CR3","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1056\/NEJMoa1714519","volume":"378","author":"C Corpechot","year":"2018","unstructured":"Corpechot\u00a0C, Chazouill\u00e8res\u00a0O, Rousseau\u00a0A, Le Gruyer\u00a0A, Habersetzer\u00a0F, Mathurin\u00a0P, Goria\u00a0O, Potier\u00a0P, Minello\u00a0A, Silvain\u00a0C, Abergel\u00a0A, Debette-Gratien\u00a0M, Larrey\u00a0D, Roux\u00a0O, Bronowicki\u00a0JP, Boursier\u00a0J, de Ledinghen\u00a0V, Heurgue-Berlot\u00a0A, Nguyen-Khac\u00a0E, Zoulim\u00a0F, Ollivier-Hourmand\u00a0I, Zarski\u00a0JP, Nkontchou\u00a0G, Lemoinne\u00a0S, Humbert\u00a0L, Rainteau\u00a0D, Lef\u00e8vre\u00a0G, de Chaisemartin\u00a0L, Chollet-Martin\u00a0S, Gaouar\u00a0F, Admane\u00a0FH, Simon\u00a0T, Poupon R. A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis. N Engl J Med. (2018) Jun 7. PMID: 378(23):2171\u20132181. https:\/\/doi.org\/10.1056\/NEJMoa1714519 (29874528)","journal-title":"PMID:"},{"issue":"2","key":"1730_CR4","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1111\/apt.17755","volume":"59","author":"MJ Mayo","year":"2024","unstructured":"Mayo\u00a0MJ, Vierling\u00a0JM, Bowlus\u00a0CL, Levy\u00a0C, Hirschfield\u00a0GM, Neff\u00a0GW, Galambos\u00a0MR, Gordon\u00a0SC, Borg\u00a0BB, Harrison\u00a0SA, Thuluvath\u00a0PJ, Goel\u00a0A, Shiffman\u00a0ML, Swain\u00a0MG, Jones\u00a0DEJ, Trivedi\u00a0P, Kremer\u00a0AE, Aspinall\u00a0RJ, Sheridan\u00a0DA, D\u00f6rffel\u00a0Y, Yang\u00a0K, Choi\u00a0YJ, McWherter\u00a0CA (2024) Open-label, clinical trial extension: Two-year safety and efficacy results of seladelpar in patients with primary biliary cholangitis. Aliment Pharmacol Ther 59(2):186\u2013200 (Jan)","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Die Innere Medizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-024-01730-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-024-01730-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-024-01730-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T13:03:52Z","timestamp":1724936632000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-024-01730-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,21]]},"references-count":4,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["1730"],"URL":"https:\/\/doi.org\/10.1007\/s00108-024-01730-2","relation":{},"ISSN":["2731-7080","2731-7099"],"issn-type":[{"type":"print","value":"2731-7080"},{"type":"electronic","value":"2731-7099"}],"subject":[],"published":{"date-parts":[[2024,8,21]]},"assertion":[{"value":"16 May 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"V.\u00a0Keitel-Anselmino erhielt Vortragshonorare von Gilead und Ipsen und Falk. S.\u00a0Nitschmann gibt an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}